A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer.
Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), José Baselga(Novartis (Switzerland)), Javier Cortés(Villa Maria Hospital), T. Zhang, Lamar Eaton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yixuan Song, Joanne L. Blum(Brigham and Women's Hospital), H. S. Rugo, Charles Swanton(The Francis Crick Institute)
Cited by 5
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k